Abstract: The presently disclosed subject matter provides for chimeric receptors that target MUC16 and cells comprising such chimeric receptors. The presently disclosed subject matter further provides uses of the chimeric receptors for treatment.

Abstract: The present invention includes methods and compositions for modifying endothelial cells for improved vascular self-assembly. In some embodiments, the invention includes a modified endothelial cell and methods of generating and using the modified endothelial cell in a pharmaceutical composition. Other embodiments include methods of promoting vascular self-assembly and regenerating vascular structures in a subject in need thereof. In particular, the modified endothelial cell has reduced immunogenicity in an allogeneic environment in the subject, while still capable of forming vascular structures.